ZA200308185B - An assay for detecting inhibitors of the enzyme myeloperoxidase. - Google Patents
An assay for detecting inhibitors of the enzyme myeloperoxidase. Download PDFInfo
- Publication number
- ZA200308185B ZA200308185B ZA200308185A ZA200308185A ZA200308185B ZA 200308185 B ZA200308185 B ZA 200308185B ZA 200308185 A ZA200308185 A ZA 200308185A ZA 200308185 A ZA200308185 A ZA 200308185A ZA 200308185 B ZA200308185 B ZA 200308185B
- Authority
- ZA
- South Africa
- Prior art keywords
- myeloperoxidase
- taurine
- hydrogen peroxide
- detector molecule
- reacting
- Prior art date
Links
- 102000003896 Myeloperoxidases Human genes 0.000 title claims description 39
- 108090000235 Myeloperoxidases Proteins 0.000 title claims description 39
- 239000003112 inhibitor Substances 0.000 title claims description 14
- 238000003556 assay Methods 0.000 title description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical group NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 49
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 36
- 229960003080 taurine Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 claims description 17
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 17
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 102000016938 Catalase Human genes 0.000 claims description 6
- 108010053835 Catalase Proteins 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 238000002835 absorbance Methods 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003622 mature neutrocyte Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- -1 aromatic amino acids Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000680 phagosome Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UCDLBNQQNRQANR-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-2,4-dien-1-amine Chemical compound CC1(C)C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 UCDLBNQQNRQANR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical class C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- PMJHNEFCWLUZBC-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1=C(N)C(C)(C)CC(C=2C=C(C)C(N)=CC=2)=C1 PMJHNEFCWLUZBC-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2001/001014 WO2001085146A1 (en) | 2000-05-12 | 2001-05-08 | Pharmaceutical compounds for treating copd |
| SE0103766A SE0103766D0 (sv) | 2001-11-09 | 2001-11-09 | Novel assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200308185B true ZA200308185B (en) | 2004-07-05 |
Family
ID=20285957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200308185A ZA200308185B (en) | 2001-05-08 | 2003-10-21 | An assay for detecting inhibitors of the enzyme myeloperoxidase. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7108997B2 (sv) |
| KR (1) | KR100879700B1 (sv) |
| BR (1) | BR0209446A (sv) |
| CY (1) | CY1107345T1 (sv) |
| HK (1) | HK1061700A1 (sv) |
| MX (1) | MXPA03010143A (sv) |
| NO (1) | NO20034951D0 (sv) |
| PT (1) | PT1387893E (sv) |
| SE (1) | SE0103766D0 (sv) |
| ZA (1) | ZA200308185B (sv) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| SE0402591D0 (sv) * | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| WO2011133581A1 (en) | 2010-04-19 | 2011-10-27 | General Atomics | Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples |
| CA2839747A1 (en) | 2011-07-11 | 2013-01-17 | Exoxemis, Inc. | Eosinophil peroxidase compositions and methods of their use |
| US20150099010A1 (en) | 2013-10-07 | 2015-04-09 | Reoxcyn Discoveries Group, Inc | Redox signaling gel formulation |
| US10485827B2 (en) | 2016-01-19 | 2019-11-26 | Rdg Holdings, Inc. | Topical eye serum compositions, methods or preparing, and methods of use |
| US11857674B2 (en) | 2016-05-18 | 2024-01-02 | Reoxcyn, Llc | Lubricant formulations |
| US9474768B1 (en) | 2016-05-18 | 2016-10-25 | Reoxcyn Discoveries Group, Inc. | Lubricant formulations |
| US9833471B1 (en) | 2016-09-15 | 2017-12-05 | Reoxcyn Discoveries Group, Inc. | Hypochlorous acid-based hand sanitizer |
| US20180200165A1 (en) | 2017-01-16 | 2018-07-19 | Reoxcyn Innovation Group, Llc | Dentifrice formulations and methods of oral care |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046019A (en) * | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
| US5976823A (en) * | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
-
2001
- 2001-11-09 SE SE0103766A patent/SE0103766D0/sv unknown
-
2002
- 2002-05-06 KR KR1020037014493A patent/KR100879700B1/ko not_active IP Right Cessation
- 2002-05-06 MX MXPA03010143A patent/MXPA03010143A/es active IP Right Grant
- 2002-05-06 BR BR0209446-0A patent/BR0209446A/pt not_active IP Right Cessation
- 2002-05-06 US US10/476,999 patent/US7108997B2/en not_active Expired - Fee Related
- 2002-05-06 PT PT02728295T patent/PT1387893E/pt unknown
-
2003
- 2003-10-21 ZA ZA200308185A patent/ZA200308185B/en unknown
- 2003-11-06 NO NO20034951A patent/NO20034951D0/no not_active Application Discontinuation
-
2004
- 2004-06-28 HK HK04104619A patent/HK1061700A1/xx not_active IP Right Cessation
-
2007
- 2007-02-23 CY CY20071100257T patent/CY1107345T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1107345T1 (el) | 2012-12-19 |
| HK1061700A1 (en) | 2004-09-30 |
| KR100879700B1 (ko) | 2009-01-21 |
| US20040142407A1 (en) | 2004-07-22 |
| MXPA03010143A (es) | 2004-05-21 |
| PT1387893E (pt) | 2007-02-28 |
| SE0103766D0 (sv) | 2001-11-09 |
| BR0209446A (pt) | 2004-08-03 |
| KR20030094389A (ko) | 2003-12-11 |
| US7108997B2 (en) | 2006-09-19 |
| NO20034951D0 (no) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shacter et al. | Inhibition of the myeloperoxidase-H2O2-Cl− system of neutrophils by indomethacin and other non-steroidal anti-inflammatory drugs | |
| ZA200308185B (en) | An assay for detecting inhibitors of the enzyme myeloperoxidase. | |
| Schuler et al. | Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreductase established by photoaffinity labeling | |
| Zheng et al. | Highly sensitive fluorescence detection of heparin based on aggregation-induced emission of a tetraphenylethene derivative | |
| US20170016924A1 (en) | Methods for assessing the risk for development of cardiovascular disease | |
| EP0878716B1 (en) | Measurement of LDL-cholesterol | |
| ES2263476T3 (es) | Procedimiento de pretratamiento de una muestra para cuantificar el colesterol y procedimiento para cuantificar el colesterol en lipoproteinas especificas usando dicho procedimiento. | |
| Mueller et al. | Fast and sensitive chemiluminescence determination of H2O2 concentration in stimulated human neutrophils | |
| EP1387893B1 (en) | An assay for detecting inhibitors of the enzyme myeloperokidase | |
| JP5118321B2 (ja) | ヘパリン修飾成分を用いた第Ｘａ因子に基づくヘパリンアッセイ | |
| AU2002258327A1 (en) | An assay for detecting inhibitors of the enzyme myeloperoxidase | |
| EP2167676B1 (en) | Kit for the sequential measurement of (1) the enzymatically active fraction and (2) the total amount of an enzyme | |
| US6927038B2 (en) | Total cysteine assay | |
| WO2008002911A2 (en) | Urate metabolites as diagnostic markers for cardiovascular and renal disease | |
| JP4081709B2 (ja) | 夾雑物質による影響回避方法 | |
| US20060188997A1 (en) | Detection of superoxide ions | |
| JP2001255331A (ja) | アスコルビン酸の分析方法及び分析用試薬 | |
| JPH0153040B2 (sv) | ||
| JPH0457218B2 (sv) | ||
| AU2005202380A1 (en) | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same |